InSilicoMinds was honored to meet with ๐๐ซ. ๐๐๐ง๐จ๐ฃ ๐๐จ๐ฌ๐ก๐ข, ๐๐๐, Department Of Pharmaceuticals (DoP), Ministry Of Chemicals & Fertilizers – Government Of India, to discuss how India can become a global leader in In Silico, which includes Computational Modeling & Simulation and AI driven biopharma innovation under the Biopharma SHAKTI Mission.
The conversation focused on a core belief we strongly share and our leading in the country as an organization: Indiaโs next chapter in pharma will not only be built on manufacturing scale โ but on leadership in AI, computational modeling & simulation, regulatory science, and accelerated biopharma innovation.
๐๐๐๐ ๐๐ ๐กโ๐ ๐๐๐ฆ ๐๐๐๐๐ ๐๐๐ ๐๐ข๐ ๐ ๐๐ ๐๐๐๐๐ข๐๐๐:
- How in silico approaches can strengthen Indiaโs biosimilar, complex generic, peptide, and novel biologics ecosystem through Model-Informed Drug Development (MIDD) and virtual bioequivalence/biosimilarity
- Expanding access to regulatory-grade modeling & simulation capabilities across industry, academia, and emerging biotech ecosystems
- Supporting advanced computational and AI infrastructure through national research and innovation ecosystems to enable scalable in silico R&D across India
- Prioritizing skilling and regulatory capacity building at the CDSCO around In Silico: PBPK, MIDD, AI-enabled regulatory science, and model-informed evidence evaluation
- Exploring how AI and in silico approaches can complement broader Biopharma SHAKTI initiatives to improve development efficiency, reduce costs, accelerate timelines, and strengthen Indiaโs global competitiveness
- The growing global momentum around NAMs (Non-Animal Methods), in silico evidence generation, and ICH M15 harmonization across international regulatory agencies
India has a unique opportunity to lead at the intersection of pharma, biotech, AI, and computational science.
